Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 123, Issue 1, 1997, Pages 25-30

  Sadeghi, Nader ^a   Black, Martin J ^a   Hier, Michael P ^a   Shenouda, George ^a   Karp, Stephen E ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; DOSE RESPONSE; DRUG EFFICACY; HEAD AND NECK CANCER; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MOUSE; NONHUMAN; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION;

EID: 0031018379     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1997.01900010029004     Document Type: Article

References (30)

1. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 1953;13:835-841.
2. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957;18:769-774.
3. Klein GH, Sjogren HO, Klein E, Hellström KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960;20:1561-1572.
4. Shu S, Chou T, Rosenberg SA. In vitro sensitization and expansion with viable tumor cells and IL-2 in the generation of specific therapeutic effector cells. J Immunol. 1986;136:3891-3898.
5. Shu S, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol. 1987;139:295-304.
6. Chou T, Chang AE, Shu S. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. J Immunol. 1988;140:2453-2461.
7. Chou T, Bertera S, Chang AE, Shu S. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol. 1988;141:1775-1781.
8. Shu S, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrates therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol. 1989;143:740-748.
9. Voshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol. 1991;147:729-737.
10. Yoshizawa H, Sakai K, Chang AE, Shu S. Activation by anti-CD3 of tumor-draining node cells for specific adoptive immunotherapy. Cell Immunol. 1991;134:473-479.
11. Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondac VK, Shu S. Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 1993;53:1043-1050.
12. Mickel RA, Kessler DJ, Taylor JMG, Lichtenstein A. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Cancer Res. 1988;48:5017-5022.
13. Wang MB, Lichtenstein A, Mickel RA. Hierarchial immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 1991;105:517-527.
14. Shiloni E, Karp SE, Custer MC, et al. Retroviral transduction of interferon-γ cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. Cancer Immunol Immunother. 1993;37:286-292.
15. McGrath PC, Hamby LS, Freeman JW. Phorbol dibutyrate plus ionomycin improves the generation of cytotoxic T cells from draining lymph nodes of patients with advanced head and neck cancer. Am J Surg. 1992;164:610-614.
16. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976;33:241-259.
17. Hewitt HB. Second point: animal tumor models and their relevance to human tumor immunology. J Biol Resp Modifiers. 1983;2:210-216.
18. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwartz S. Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med. 1985;161:1169-1188.
19. Rosenberg SA, Lotze MD, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-897.
20. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9:694-704.
21. Shultz-Hector S, Haghayegh S. Beta fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res. 1993;53:1444-1449.
22. Hier MP, Black MJ, Shenouda G, Sadeghi N, Karp SE. A murine model for the immunotherapy of head and neck squamous cell carcinoma. Laryngoscope. 1995;105:1077-1080.
23. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A. 1987;84:1374-1378.
24. Wexler H. Accurate identification of experimental pulmonary metastasis. J Natl Cancer Inst. 1966;36:641-643.
25. Kruskal WH, Wallis WA. Use of ranks in one-criterion variants analysis. J Am Stat Assoc. 1952;47:583-588.
26. Matsumura T, Krinock RA, Chang AE, Shu S. Cross reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor. Cancer Res. 1993;53:4315-4321.
27. Yasumura S, Hirabayashi H, Schwartz DR, et al. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res. 1993;53:1461-1468.
28. Whiteside TL, Letessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993;53:5654-5662.
29. Melioli G, Margarino G, Scala M, et al. Perilymphatic injections of recombinanl interleukin-2 partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma. Laryngoscope. 1992;102:572-578.
30. Mattijssen V, De Mulder PH, Schornagel JH, et al. Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. J Immunother Emphasis Tumor Immunol. 1991;10:63-68.